These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 20160206)

  • 41. Alzheimer's disease: beware of interactions with cholinesterase inhibitors.
    Prescrire Int; 2006 Jun; 15(83):103-6. PubMed ID: 16764099
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A 12-month study of the efficacy of rivastigmine in patients with advanced moderate Alzheimer's disease.
    Karaman Y; Erdoğan F; Köseoğlu E; Turan T; Ersoy AO
    Dement Geriatr Cogn Disord; 2005; 19(1):51-6. PubMed ID: 15383747
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Alzheimer disease. Pseudo-irreversible AChE inhibition with rivastigmine].
    Med Monatsschr Pharm; 1998 Aug; 21(8):248-9. PubMed ID: 9758554
    [No Abstract]   [Full Text] [Related]  

  • 44. Position statement of the American Association for Geriatric Psychiatry regarding principles of care for patients with dementia resulting from Alzheimer disease.
    Lyketsos CG; Colenda CC; Beck C; Blank K; Doraiswamy MP; Kalunian DA; Yaffe K;
    Am J Geriatr Psychiatry; 2006 Jul; 14(7):561-72. PubMed ID: 16816009
    [No Abstract]   [Full Text] [Related]  

  • 45. Realistic expectations for treatment success in Alzheimer's disease.
    Geldmacher DS; Frolich L; Doody RS; Erkinjuntti T; Vellas B; Jones RW; Banerjee S; Lin P; Sano M
    J Nutr Health Aging; 2006; 10(5):417-29. PubMed ID: 17066215
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Brain functional imaging of frontotemporal lobar degeneration].
    Nakano S; Matsuda H
    Brain Nerve; 2009 Nov; 61(11):1275-84. PubMed ID: 19938684
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Patterns of cholinesterase-inhibitor use in the nursing home setting: a retrospective analysis.
    Dybicz SB; Keohane DJ; Erwin WG; McRae T; Shah SN
    Am J Geriatr Pharmacother; 2006 Jun; 4(2):154-60. PubMed ID: 16860262
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Alarming arbitrariness in EU prescription and reimbursement criteria for anti-dementia drugs.
    Oude Voshaar RC; Burns A; Olde Rikkert MG;
    Int J Geriatr Psychiatry; 2006 Jan; 21(1):29-31. PubMed ID: 16353176
    [No Abstract]   [Full Text] [Related]  

  • 49. Effect of rivastigmine on tremor in patients with Parkinson's disease and dementia.
    Gurevich TY; Shabtai H; Korczyn AD; Simon ES; Giladi N
    Mov Disord; 2006 Oct; 21(10):1663-6. PubMed ID: 16941467
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Frontotemporal dementia: a review].
    Chauvire V; Even C; Thuile J; Rouillon F; Guelfi JD
    Encephale; 2007 Dec; 33(6):933-40. PubMed ID: 18789785
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Frontotemporal dementia: recommendations for therapeutic studies, designs, and approaches.
    Freedman M
    Can J Neurol Sci; 2007 Mar; 34 Suppl 1():S118-24. PubMed ID: 17469694
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A systematic review of the effectiveness of rivastigmine for the treatment of behavioral disturbances in dementia and other neurological disorders.
    Figiel G; Sadowsky C
    Curr Med Res Opin; 2008 Jan; 24(1):157-66. PubMed ID: 18036286
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Progress and Challenges in Frontotemporal Dementia Research: A 20-Year Review.
    Hodges JR; Piguet O
    J Alzheimers Dis; 2018; 62(3):1467-1480. PubMed ID: 29504536
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Rivastigmine in Parkinson's disease dementia: profile report.
    Siddiqui MA; Wagstaff AJ
    Drugs Aging; 2007; 24(3):255-9. PubMed ID: 17362052
    [No Abstract]   [Full Text] [Related]  

  • 55. Management of inappropriate sexual behaviors in dementia: a literature review.
    Tucker I
    Int Psychogeriatr; 2010 Aug; 22(5):683-92. PubMed ID: 20226113
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A systematic review of neurotransmitter deficits and treatments in frontotemporal dementia.
    Huey ED; Putnam KT; Grafman J
    Neurology; 2006 Jan; 66(1):17-22. PubMed ID: 16401839
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cannabinoids in the management of frontotemporal dementia: a case series.
    Gopalakrishna G; Srivathsal Y; Kaur G
    Neurodegener Dis Manag; 2021 Feb; 11(1):61-64. PubMed ID: 33190583
    [No Abstract]   [Full Text] [Related]  

  • 58. Frontotemporal degeneration, the next therapeutic frontier: molecules and animal models for frontotemporal degeneration drug development.
    Boxer AL; Gold M; Huey E; Gao FB; Burton EA; Chow T; Kao A; Leavitt BR; Lamb B; Grether M; Knopman D; Cairns NJ; Mackenzie IR; Mitic L; Roberson ED; Van Kammen D; Cantillon M; Zahs K; Salloway S; Morris J; Tong G; Feldman H; Fillit H; Dickinson S; Khachaturian Z; Sutherland M; Farese R; Miller BL; Cummings J
    Alzheimers Dement; 2013 Mar; 9(2):176-88. PubMed ID: 23043900
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Frontotemporal dementia: therapeutic interventions.
    Mendez MF
    Front Neurol Neurosci; 2009; 24():168-178. PubMed ID: 19182475
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The advantages of frontotemporal degeneration drug development (part 2 of frontotemporal degeneration: the next therapeutic frontier).
    Boxer AL; Gold M; Huey E; Hu WT; Rosen H; Kramer J; Gao FB; Burton EA; Chow T; Kao A; Leavitt BR; Lamb B; Grether M; Knopman D; Cairns NJ; Mackenzie IR; Mitic L; Roberson ED; Van Kammen D; Cantillon M; Zahs K; Jackson G; Salloway S; Morris J; Tong G; Feldman H; Fillit H; Dickinson S; Khachaturian ZS; Sutherland M; Abushakra S; Lewcock J; Farese R; Kenet RO; Laferla F; Perrin S; Whitaker S; Honig L; Mesulam MM; Boeve B; Grossman M; Miller BL; Cummings JL
    Alzheimers Dement; 2013 Mar; 9(2):189-98. PubMed ID: 23062850
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.